Pharmacologic treatment of male breast cancer

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 15, 2009, Pages 2499-2510

  Hayes, Teresa G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatase; Chemotherapy; Hormonal therapy; Male breast cancer; Orchiectomy; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CALUSTERONE; CYCLOPHOSPHAMIDE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTROGEN; EXEMESTANE; FLUOROURACIL; GESTAGEN; GLUCOCORTICOID; GONADORELIN DERIVATIVE; GOSERELIN; HORMONE; KETOCONAZOLE; LETROZOLE; MEDROXYPROGESTERONE; MEGESTROL ACETATE; MELPHALAN; METHOTREXATE; PREDNISONE; STEROID; TAMOXIFEN; THIOTEPA; UNINDEXED DRUG; VINCRISTINE;

ADJUVANT THERAPY; ADRENAL SUPPRESSION; ADRENALECTOMY; ASEPTIC NECROSIS; BREAST CANCER; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CATARACT; CLINICAL FEATURE; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; CUSHING SYNDROME; DISEASE SEVERITY; DISTANT METASTASIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EPIDEMIOLOGICAL DATA; FEMINIZATION; GYNECOMASTIA; HOT FLUSH; HUMAN; LIBIDO DISORDER; MALE; MASTECTOMY; META ANALYSIS; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; NAUSEA; ORCHIECTOMY; OSTEOPOROSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PROGNOSIS; REVIEW; SURGICAL TECHNIQUE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; VENOUS THROMBOEMBOLISM;

AGE FACTORS; ANDROGENS; ANTINEOPLASTIC AGENTS; BRCA2 PROTEIN; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MUTATION; NEOPLASM STAGING; PROGNOSIS;

EID: 70349391149     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903200634     Document Type: Review

References (195)

1. Jemal A, Siegel R, Ward E, etal. Cancer statistics, 2009. CA Cancer J Clin 2009;59(4):225-249
2. Csokay B, Udvarhelyi N, Sulyok Z, et al. High frequency of germ-line BRCA2 mutations among Hungarian male breast cancer patients without family history. Cancer Res 1999;59(5):995-998 (Pubitemid 29135956)
3. El-Gazayerli MM, Abdel-Aziz AS. On Bilharziasis and male breast cancer in Egypt: a preliminary report and review of the literature. Br J Cancer 1963;17:566-571
4. Bhagwandeen SB. Carcinoma of the male breast in Zambia. East Afr Med J 1972;49(2):89-93
5. Ojara EA. Carcinoma of the male breast in Mulago Hospital, Kampala. East Afr Med J 1978;55(10):489-491 (Pubitemid 9232573)
6. Donegan WL, Redlich PN. Breast cancer in men. Surg Clin North Am 1996;76(2):343-363
7. Ravandi-Kashani F, Hayes TG. Male breast cancer: a review of the literature. Eur J Cancer 1998;34(9):1341-1347 (Pubitemid 28370923)
8. Thomas DB. Breast cancer in men. Epidemiol Rev 1993;15(1):220-231
9. English JC 3rd, Middleton C, Patterson JW, Slingluff CL. Cancer of the male breast. Int J Dermatol 2000;39(12):881-886
10. Nirmul D, Pegoraro RJ, Jialal I, et al. The sex hormone profile of male patients with breast cancer. Br J Cancer 1983;48(3):423-427
11. Srinivasan G, Srinivasan U, Greiver P. Male breast carcinoma following estrogen therapy: report of a case. J Ky Med Assoc 1979;77(1):9-10,48 (Pubitemid 9092362)
12. Schlappack OK, Braun O, Maier U. Report of two cases of male breast cancer after prolonged estrogen treatment for prostatic carcinoma. Cancer Detect Prev 1986;9(3-4):319-322
13. Pritchard TJ, Pankowsky DA, Crowe JP, Abdul-karim FW. Breast cancer in a male-to-female transsexual. A case report. JAMA 1988;259(15):2278-2280
14. Ganly I, Taylor EW. Breast cancer in a trans-sexual man receiving hormone replacement therapy. Br J Surg 1995;82(3):341
15. Symmers WS. Carcinoma of breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics. Br Med J 1968;2(5597):83-85
16. Medras M, Filus A, Jozkow P, etal. Breast cancer and long-term hormonal treatment of male hypogonadism. Breast Cancer Res Treat 2006;96(3):263-265
17. Lee SC, Ellis RJ. Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004;96(4):338-339 (Pubitemid 38256281)
18. Hirose Y, Sasa M, Bando Y, etal. Bilateral male breast cancer with male potential hypogonadism. World J Surg Oncol 2007;5:60 (Pubitemid 46965054)
19. Jackson AW, Muldal S, Ockey CH, O'Connor PJ. Carcinoma of male breast in association with the Klinefelter syndrome. Br Med J 1965;1(5429):223-225
20. Scheike O, Visfeldt J, Petersen B. Male breast cancer. 3. Breast carcinoma in association with the Klinefelter syndrome. Acta Pathol Microbiol Scand [A] 1973;81(3):352-358
21. Hultborn R, Hanson C, Kopf I, et al. Prevalence of Klinefelter's syndrome in male breast cancer patients. Anticancer Res 1997;17(6D):4293-4297 (Pubitemid 28081702)
22. Harnden DG, Maclean N, Langlands AO. Carcinoma of the breast and Klinefelter's syndrome. J Med Genet 1971;8(4):460-461
23. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006;367(9510):595-604
24. Thorlacius S, Tryggvadottir L, Olafsdottir GH, etal. Linkage to BRCA2 region in hereditary male breast cancer. Lancet 1995;346(8974):544-545
25. Couch FJ, Farid LM, Deshano ML, et al. BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet 1996;13(1):123-125 (Pubitemid 126528243)
26. Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res 1998;58(7):1367-1371 (Pubitemid 28193591)
27. Syrjakoski K, Kuukasjarvi T, Waltering K, et al. BRCA2 mutations in 154 Finnish male breast cancer patients. Neoplasia 2004;6(5):541-545 (Pubitemid 39411091)
28. Friedman LS, Gayther SA, Kurosaki T, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60(2):313-319 (Pubitemid 27058403)
29. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 2002;20(6):1480-1490
30. Basham VM, Lipscombe JM, Ward JM, et al. BRCA1 and BRCA2 mutations in a population-based study of male breast cancer. Breast Cancer Res 2002;4(1):R2 (Pubitemid 34097557)
31. Fackenthal JD, Marsh DJ, Richardson AL, et al. Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001;38(3):159-164 (Pubitemid 32250866)
32. Meijers-Heijboer H, van den Ouweland A, et al. CHEK2-breast cancer consortium. Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002;31(1):55-59
33. Wasielewski M, den Bakker MA, van den Ouweland A, etal. CHEK2 1100delC and male breast cancer in the Netherlands. Breast Cancer Res Treat 2009;116(2):397-400. [Epub 31 Aug 2008]
34. Syrjakoski K, Kuukasjarvi T, Auvinen A, Kallioniemi OP. CHEK2 1100delC is not a risk factor for male breast cancer population. Int J Cancer 2004;108(3):475-476 (Pubitemid 37553160)
35. Ohayon T, Gal I, Baruch RG, et al. CHEK2*1100delC and male breast cancer risk in Israel. Int J Cancer 2004;108(3):479-480 (Pubitemid 37549616)
36. Hemsell DL, Grodin JM, Brenner PF, et al. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38(3):476-479
37. Griffin JF, Wilson JD. Disorders of the testes. In: Isselbacher KJ, editor, Harrison's Principles of Internal Medicine. 13th edition. New York: Mc-Graw-Hill, Inc.; 1994. p. 2006-2017
38. Orth DN, Kovacs WJ. The adrenal cortex. In: Wilson JD, editor, Williams Textbook of Endocrinology. 9th edition. Philadelphia: W.B.Saunders Company; 1998. p. 517-664
39. Bhasin S, Jameson JL. Disorders of the testes and male reproductive system In: Fauci AS, Kasper DL, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al, editors, Harrison's Principles of Internal Medicine. 17th edition. The McGraw-Hill Companies, Inc.; 2008
40. Simpson ER. Role of aromatase in sex steroid action. J Mol Endocrinol 2000;25(2):149-156
41. Sasano H, Ozaki M. Aromatase expression and its localization in human breast cancer. J Steroid Biochem Mol Biol 1997;61(3-6):293-298 (Pubitemid 27455692)
42. Dakin Hachè K, Gray S, Barnes PJ, et al. Clinical and pathological correlations in male breast cancer: intratumoral aromatase expression via tissue microarray. Breast Cancer Res Treat 2007;105(2):169-175 (Pubitemid 47366886)
43. Hamilton A, Volm M. Nonsteroidal and steroidal aromatase inhibitors in breast cancer. Oncology (Williston Park) 2001;15(8):965-72; discussion 72, 77-79 (Pubitemid 33739186)
44. Rayson D, Erlichman C, Suman VJ, et al. Molecular markers in male breast carcinoma. Cancer 1998;83(9):1947-1955 (Pubitemid 28503726)
45. Ruff SJ, Bauer JE, Keenan EJ, et al. Hormone receptors in male breast carcinoma. J Surg Oncol 1981;18(1):55-59 (Pubitemid 11021098)
46. Nomura Y, Kondo H, Yamagata J, Takenaka K. Detection of the estrogen receptor and response to endocrine therapy in male breast cancer patients. Gann 1977;68(3):333-336 (Pubitemid 8136477)
47. Everson RB, Lippman ME, Thompson EB, et al. Clinical correlations of steroid receptors and male breast cancer. Cancer Res 1980;40(4):991-997 (Pubitemid 10135797)
48. Gupta N, Cohen JL, Rosenbaum C, Raam S. Estrogen receptors in male breast cancer. Cancer 1980;46(8):1781-1784 (Pubitemid 10011132)
49. Mercer RJ, Bryan RM, Bennett RC. Hormone receptors in male breast cancer. Aust N Z J Surg 1984;54(3):215-218 (Pubitemid 14014753)
50. Morimoto T, Komaki K, Yamakawa T, et al. Cancer of the male breast. J Surg Oncol 1990;44(3):180-184
51. Davis SL, Barse F, Meoli FG. Male breast carcinoma: clinical experience in a suburban community. J Am Osteopath Assoc 1992;92(8):1005-6, 13-16
52. Cutuli B, Lacroze M, Dilhuydy JM, et al. Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 1995;31A(12):1960-1964 (Pubitemid 26023085)
53. Williams WL Jr, Powers M, Wagman LD. Cancer of the male breast: a review. J Natl Med Assoc 1996;88(7):439-443
54. Munoz de Toro MM, Maffini MV, Kass L, Luque EH. Proliferative activity and steroid hormone receptor status in male breast carcinoma. J Steroid Biochem Mol Biol 1998;67(4):333-339 (Pubitemid 28559231)
55. Pich A, Margaria E, Chiusa L, et al. Androgen receptor expression in male breast carcinoma: lack of clinicopathological association. Br J Cancer 1999;79(5-6):959-964 (Pubitemid 29082133)
56. Meijer-van Gelder ME, Look MP, Bolt-de Vries J, etal. Clinical relevance of biologic factors in male breast cancer. Breast Cancer Res Treat 2001;68(3):249-260
57. Weber-Chappuis K, Bieri-Burger S, Hurlimann J. Comparison of prognostic markers detected by immunohistochemistry in male and female breast carcinomas. Eur J Cancer 1996;32A(10):1686-1692 (Pubitemid 26306878)
58. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998;83(3):498-509 (Pubitemid 28354506)
59. Calandra RS, Charreau EH, Royer de Giaroli M, Baldi A. Incidence of estrogen, progesterone and prolactin receptors in human breast cancer. Prog Clin Biol Res 1984;142:97-108
60. Kidwai N, Gong Y, Sun X, etal. Expression of androgen receptor and prostate-specific antigen in male breast carcinoma. Breast Cancer Res 2004;6(1):R18-23
61. Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. Cancer 2004;101(1):51-57
62. Anderson WF. The descriptive epidemiology of male versus female breast cancer, using age-period-cohort (APC) models. 2008 ASCO Breast Cancer Symposium:abstract 93
63. Anderson WF, Chu KC, Chatterjee N, Brinton LA. Male breast cancer (MBC) in the SEER database. Proc Annu Meet Am Soc Clin Oncol 2001;20:A1691
64. Romain S, Laine Bidron C, Martin PM, Magdelenat H. Steroid receptor distribution in 47,892 breast cancers. A collaborative study of 7 European laboratories. The EORTC Receptor Study Group. Eur J Cancer 1995;31A(3):411-417
65. El-Tamer M, Hibshoosh H, Troxel A. Estrogen and progesterone receptors: comparison in age-matched men and women with breast cancer. Program and abstracts of the 23rd Annual San Antonio Breast Cancer Symposium; December 6-9, 2000. Breast Cancer Res Treat 2000;64:128
66. Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001;182(4):389-392 (Pubitemid 33079093)
67. Barlund M, Kuukasjarvi T, Syrjakoski K, et al. Frequent amplification and overexpression of CCND1 in male breast cancer. Int J Cancer 2004;111(6):968-971 (Pubitemid 39096248)
68. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137(8):678-687
69. Joshi MG, Lee AK, Loda M, etal. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996;77(3):490-498
70. Shpitz B, Bomstein Y, Sternberg A, et al. Angiogenesis, p53 and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J Surg Oncol 2000;75(4):252-257
71. Bines J, Goss B, Hussong J, etal. C-erb-B2 and p53 overexpression as predictors of survival in patients with male breast cancer. Proc Annu Meet Am Soc Clin Oncol 1997;16:A558
72. Rudlowski C, Friedrichs N, Faridi A, et al. Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 2004;84(3):215-223 (Pubitemid 38445371)
73. Avisar E, McParland E, Dicostanzo D, Axelrod D. Prognostic factors in node-negative male breast cancer. Clin Breast Cancer 2006;7(4):331-335 (Pubitemid 44717766)
74. Rudlowski C, Schulten HJ, Golas MM, et al. Comparative genomic hybridization analysis on male breast cancer. Int J Cancer 2006;118(10):2455- 2460
75. Andre S, Pinto AE, Laranjeira C, et al. Male and female breast cancer-differences in DNA ploidy, p21 and p53 expression reinforce the possibility of distinct pathways of oncogenesis. Pathobiology 2007;74(6):323-327 (Pubitemid 350273703)
76. Fassan MBR, Palazzo JP, Lloyd J, et al. MicroRNA expression profiling of male breast cancer. 2008 ASCO Breast Cancer Symposium:abstract 125
77. Shak S, Palmer G, Baehner FL, et al. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol 2009;27(15s):abstract 549
78. Breast Cancer. NCCN practice guidelines in oncology 2009. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
79. Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25(3):235-237 (Pubitemid 34602542)
80. PDQ® . Male breast cancer treatment. National cancer institute 2009. Available from: http://www.cancer.gov/cancertopics/pdq/treatment/malebreast/ Patient
81. Golshan M, Rusby J, Dominguez F, Smith BL. Breast conservation for male breast carcinoma. Breast 2007;16(6):653-656
82. Herrmann JB. The effect of hormonal imbalance on advanced carcinoma of the male breast. Ann Surg 1951;133(2):191-199
83. Hultborn R, Friberg S, Hultborn KA, et al. Male breast carcinoma. II. A study of the total material reported to the Swedish Cancer Registry 1958 - 1967 with respect to treatment, prognostic factors and survival. Acta Oncol 1987;26(5):327-341
84. Kraybill WG, Kaufman R, Kinne D. Treatment of advanced male breast cancer. Cancer 1981;47(9):2185-2189 (Pubitemid 11098587)
85. Neifeld JP, Meyskens F, Tormey DC, Javadpour N. The role of orchiectomy in the management of advanced male breast cancer. Cancer 1976;37(2):992-995
86. Treves N. The treatment of cancer, especially inoperable cancer of the male breast, by ablative surgery (orchiectomy, adrenalectomy, and hypophysectomy) and hormone therapy (estrogens and corticosteroids); an analysis of 42 patients. Cancer 1959;12(4):820-832
87. Kantarjian H, Yap HY, Hortobagyi G, et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med 1983;143(2):237-240 (Pubitemid 13188577)
88. Labrie F, Dupont A, Belanger A, et al. Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 1990;13(5):275-278 (Pubitemid 20367956)
89. Borgen PI. Male breast cancer. Semin Surg Oncol 1991;7(5):314-319
90. Doberauer C, Niederle N, Schmidt CG. Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 1988;62(3):474-478 (Pubitemid 18176725)
91. Lopez M, Barduagni A. Cyproterone acetate in advanced male breast cancer. Cancer 1982;49(1):9-11 (Pubitemid 12196128)
92. Vorobiof DA, Falkson G. Nasally administered buserelin inducing complete remission of lung metastases in male breast cancer. Cancer 1987;59(4):688-689 (Pubitemid 17018741)
93. Kennedy BJ, Kiang DT. Hypophysectomy in the treatment of advanced cancer of the male breast. Cancer 1972;29(6):1606-1612
94. Lopez M, Di Lauro L, Lazzaro B, Papaldo P. Hormonal treatment of disseminated male breast cancer. Oncology 1985;42(6):345-349 (Pubitemid 16213236)
95. Harris AL, Dowsett M, Stuart-Harris R, Smith IE. Role of aminoglutethimide in male breast cancer. Br J Cancer 1986;54(4):657-660 (Pubitemid 17182696)
96. Feldman LD. Ketoconazole for male metastatic breast cancer. Ann Intern Med 1986;104(1):123-124 (Pubitemid 16182795)
97. Li MC, Janelli DE, Kelly EJ, et al. Metastatic carcinoma of the male breast treated with bilateral adrenalectomy and chemotherapy. Cancer 1970;25(3):678-681
98. Jaiyesimi IA, Buzdar AU, Sahin AA, Ross MA. Carcinoma of the male breast. Ann Intern Med 1992;117(9):771-777
99. Patel JK, Nemoto T, Dao TL. Metastatic breast cancer in males. Assessment of endocrine therapy. Cancer 1984;53(6):1344-1346
100. Ribeiro GG. The results of diethylstilboestrol therapy for recurrent and metastatic carcinoma of the male breast. Br J Cancer 1976;33(4):465-467
101. Pannuti F, Martoni A, Busutti L, et al. High-dose medroxyprogesterone acetate in advanced male breast cancer. Cancer Treat Rep 1982;66(9):1763-1765
102. Mitsuyasu R, Bonomi P, Anderson K, Fischer W Jr. Response to megestrol in male breast carcinoma. Arch Intern Med 1981;141(6):809-810 (Pubitemid 11120894)
103. Becher R, Hoffken K, Pape H, Schmidt CG. Tamoxifen treatment before orchiectomy in advanced breast cancer in men. N Engl J Med 1981;305(3):169-170 (Pubitemid 11073087)
104. Abele R, Alberto P. Tamoxifen before orchiectomy for breast cancer in men. N Engl J Med 1981;305(18):1091-1092 (Pubitemid 12234838)
105. Patterson JS, Battersby LA, Bach BK. Use of tamoxifen in advanced male breast cancer. Cancer Treat Rep 1980;64(6-7):801-804 (Pubitemid 11199497)
106. Comet B, Cutuli B, Penault-Llorca F, et al. Cancer du sein chez l'homme : revue de la littérature. Bull Cancer 2009;96(2):181-189
107. Crichlow RW, Galt SW. Male breast cancer. Surg Clin North Am 1990;70(5):1165-1177
108. Dimitrov NV, Colucci P, Nagpal S. Some aspects of the endocrine profile and management of hormone-dependent male breast cancer. Oncologist 2007;12(7):798-807 (Pubitemid 47328223)
109. Hortobagyi GN, Distefano A, Legha SS, et al. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep 1979;63(4):539-541 (Pubitemid 9217568)
110. Cantwell BM, Tong D, Minton M, et al. Tamoxifen and male breast cancer. Lancet 1978;2(8089):582-583
111. Aisner J, Ross DD, Wiernik PH. Tamoxifen in advanced male breast cancer. Arch Intern Med 1979;139(4):480-481 (Pubitemid 10150833)
112. Hilliard DA, Wilbur DW, Camacho ES. Tamoxifen response following no response to orchiectomy in metastatic male breast cancer: a case report. J Surg Oncol 1984;25(1):42-43
113. Tateishi M, Toda T, Minamisono Y, et al. A 94year old male stage IV breast cancer patient showing complete remission under tamoxifen treatment after operation. J Surg Oncol 1992;51(1):71-73
114. van Rijswijk RE, van Oostenbrugge RJ, Twijnstra A. A case of brain metastases from male breast cancer responding to tamoxifen. Eur J Cancer 1997;33(13):2282-2283 (Pubitemid 28123423)
115. Kanoh T, Iino Y, Horiguchi J, et al. A case report of advanced male breast cancer with an objective response to tamoxifen treatment. Breast Cancer 2000;7(3):256-260
116. Ribeiro G, Swindell R. Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 1992;65(2):252-254
117. Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 1994;74(1):74-77 (Pubitemid 24187612)
118. Visram H, Dent SF. Toxicities and adherence rates of hormone treatment in male breast cancer patients treated at a tertiary care center. J Clin Oncol 2009;27(suppl):abstract e11613
119. Takei H, Iino Y, Horiguchi J, et al. Tamoxifen-failed male breast cancer with a high level of circulating estrogen: report of a case. Surg Today 2001;31(2):149-151 (Pubitemid 32186564)
120. Agrawal A, Cheung KL, Robertson JF. Fulvestrant in advanced male breast cancer. Breast Cancer Res Treat 2007;101(1):123 (Pubitemid 47555327)
121. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18(22):3758-3767 (Pubitemid 30846221)
122. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000;18(22):3748-3757 (Pubitemid 30846220)
123. Howell A, Cuzick J, Baum M, etal. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-62
124. Arriola E, Hui E, Dowsett M, Smith IE. Aromatase inhibitors and male breast cancer. Clin Transl Oncol 2007;9(3):192-194
125. Pant K, Dutta U. Understanding and management of male breast cancer: a critical review. Med Oncol 2008;25(3):294-298
126. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86(3-5):225-230
127. Brueggemeier R, Hackett J, Diaz-Cruz E. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005;26(3):331-345 (Pubitemid 40686647)
128. Geisler J, King N, Dowsett M, et al. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on invivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996;74(8):1286-1291 (Pubitemid 26360121)
129. Lonning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. Breast Cancer Res Treat 1998;49(Suppl 1):S53-7; discussion S73-7
130. Mauras N, O'Brien KO, Klein KO, Hayes V. Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 2000;85(7):2370-2377 (Pubitemid 32269188)
131. Nordman IC, Dalley DN. Breast cancer in men: should aromatase inhibitors become first-line hormonal treatment? Breast J 2008;14(6):562-569
132. Nahleh ZA. Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 2006;32(2):101-105 (Pubitemid 43362231)
133. Ellinwood WE, Hess DL, Roselli CE, et al. Inhibition of aromatization stimulates luteinizing hormone and testosterone secretion in adult male rhesus monkeys. J Clin Endocrinol Metab 1984;59(6):1088-1096
134. Shetty G, Krishnamurthy H, Krishnamurthy HN, etal. Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata). Steroids 1998;63(7-8):414-420
135. Dukes M, Edwards PN, Large M, et al. The preclinical pharmacology of 'Arimidex' (anastrozole; ZD1033) - a potent, selective aromatase inhibitor. J Steroid Biochem Mol Biol 1996;58(4):439-445
136. Turner KJ, Morley M, Atanassova N, et al. Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 2000;164(2):225-238 (Pubitemid 30114670)
137. Knoche AJ, Michaud LB, Buzdar AU. Efficacy of anastrozole in a consecutive series of advanced breast cancer patients treated with multiple prior chemotherapies and endocrine agents: MD Anderson Cancer Center experience. Breast J 1999;5(3):176-181
138. Zabolotny BP, Zalai CV, Meterissian SH. Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 2005;90(1):26-30 (Pubitemid 40446471)
139. Italiano A, Largillier R, Marcy PY, et al. Rémission complète par létrozole chez un homme traité pour un cancer du sein métastatique. Rev Med Interne 2004;25(4):323-324 (Pubitemid 38438416)
140. Soon Wong N, Seong Ooi W, Pritchard K. Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain. J Clin Oncol 2007;25(24):3787 (Pubitemid 47372624)
141. Giordano SH, Hortobagyi GN. Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 2006;24(21):e42-3
142. Doyen J, Italiano A, Largillier R, et al. Aromatase inhibition in male breast cancer patients: Biological and clinical implications. J Clin Oncol 2009;27(15s):abstract 1130
143. Stewart PM. Aging and fountain-of-youth hormones. N Engl J Med 2006;355(16):1724-1726
144. Horn Y, Roof B. Male breast cancer: two cases with objective regressions from calusterone (7 alpha, 17 beta-dimethyltestosterone) after failure of orchiectomy. Oncology 1976;33(4):188-191 (Pubitemid 8045459)
145. Yap HY, Tashima CK, Blumenschein GR, et al. Chemotherapy for advanced male breast cancer. JAMA 1980;243(17):1739-1741 (Pubitemid 10148810)
146. Rivera E, Holmes FA, Frye D, et al. PhaseII study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. Cancer 2000;89(11):2195-2201
147. Alexandre J, Bleuzen P, Bonneterre J, et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18(3):562-573 (Pubitemid 30078537)
148. Lopez M, Di Lauro L, Papaldo P, Lazzaro B. Chemotherapy in metastatic male breast cancer. Oncology 1985;42(4):205-209 (Pubitemid 15015930)
149. Tranum BL, McDonald B, Thigpen T, et al. Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer 1982;49(5):835-839
150. Misset JL, Dieras V, Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999;10(5):553-560 (Pubitemid 29305433)
151. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 1989;12(2):123-128 (Pubitemid 19111590)
152. Tormey DC, Gelman R, Band PR, et al. Comparison of induction chemotherapies for metastatic breast cancer. An Eastern Cooperative Oncology Group Trial. Cancer 1982;50(7):1235-1244
153. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19(6):1707-1715 (Pubitemid 32230871)
154. Sandler B, Carman C, Perry RR. Cancer of the male breast. Am Surg 1994;60(11):816-820
155. Rudlowski C, Rath W, Becker AJ, et al. Trastuzumab and breast cancer. N Engl J Med 2001;345(13):997-998
156. Hayashi H, Kimura M, Yoshimoto N, et al. A case of HER2-positive male breast cancer with lung metastases showing a good response to trastuzumab and paclitaxel treatment. Breast Cancer 2009;16(2):136-140
157. Carmona-Bayonas A. Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast 2007;16(3):323-325 (Pubitemid 46796856)
158. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;351(9114):1451- 1467 (Pubitemid 28227036)
159. Goss PE, Reid C, Pintilie M, etal. Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret hospital during 40years: 1955 - 1996. Cancer 1999;85(3):629-639
160. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer 2005;104(11):2359-2364 (Pubitemid 41691556)
161. Vinod SK, Pendlebury SC. Carcinoma of the male breast: a review of adjuvant therapy. Australas Radiol 1999;43(1):69-72 (Pubitemid 29167004)
162. Yildirim E, Berberoglu U. Male breast cancer: a 22-year experience. Eur J Surg Oncol 1998;24(6):548-552 (Pubitemid 28566902)
163. Margaria E, Chiusa L, Ferrari L, et al. Therapy and survival in male breast carcinoma: a retrospective analysis of 50 cases. Oncol Rep 2000;7(5):1035-1039 (Pubitemid 30644118)
164. Patel HZ 2nd, Buzdar AU, Hortobagyi GN. Role of adjuvant chemotherapy in male breast cancer. Cancer 1989;64(8):1583-1585
165. Bagley CS, Wesley MN, Young RC, Lippman ME. Adjuvant chemotherapy in males with cancer of the breast. Am J Clin Oncol 1987;10(1):55-60 (Pubitemid 17007908)
166. Walshe JM, Berman AW, Vatas U, et al. A prospective study of adjuvant CMF in males with node positive breast cancer: 20-year follow-up. Breast Cancer Res Treat 2007;103(2):177-183 (Pubitemid 46789139)
167. Tamoxifen and chemotherapy US. National Institutes of Health, PDQ adult treatment editorial board 2008. Available from: http://www.nci.nih.gov/ cancertopics/pdq/treatment/breast/healthprofessional/allpages#Section-556
168. Ragaz J, Jackson SM, Le N, et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N Engl J Med 1997;337(14):956-962 (Pubitemid 27425951)
169. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337(14):949-955
170. Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6(7):1107-1117
171. Heller KS, Rosen PP, Schottenfeld D, et al. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg 1978;188(1):60-65 (Pubitemid 8373178)
172. Ciatto S, Iossa A, Bonardi R, Pacini P. Male breast carcinoma: review of a multicenter series of 150 cases. Coordinating Center and Writing Committee of FONCAM (National Task Force for Breast Cancer), Italy. Tumori 1990;76(6):555-558
173. Salvadori B, Saccozzi R, Manzari A, et al. Prognosis of breast cancer in males: an analysis of 170 cases. Eur J Cancer 1994;30A(7):930-935 (Pubitemid 24256237)
174. Rudan I, Rudan N, Basic N, et al. Differences between male and female breast cancer. III. Prognostic features. Acta Med Croatica 1997;51(3):135-141
175. Nahleh ZA, Srikantiah R, Safa M, et al. Male breast cancer in the veterans affairs population: a comparative analysis. Cancer 2007;109(8):1471- 1477 (Pubitemid 46595680)
176. Langlands AO, Maclean N, Kerr GR. Carcinoma of the male breast: report of a series of 88 cases. Clin Radiol 1976;27(1):21-25
177. Erlichman C, Murphy KC, Elhakim T. Male breast cancer: a 13-year review of 89 patients. J Clin Oncol 1984;2(8):903-909 (Pubitemid 14037768)
178. Guinee VF, Olsson H, Moller T, et al. The prognosis of breast cancer in males. A report of 335 cases. Cancer 1993;71(1):154-161
179. Willsher PC, Leach IH, Ellis IO, et al. A comparison outcome of male breast cancer with female breast cancer. Am J Surg 1997;173(3):185-188 (Pubitemid 27163845)
180. Borgen PI, Senie RT, McKinnon WM, Rosen PP. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol 1997;4(5):385-388
181. Carmalt HL, Mann LJ, Kennedy CW, et al. Carcinoma of the male breast: a review and recommendations for management. Aust N Z J Surg 1998;68(10):712-715 (Pubitemid 28435052)
182. Vetto J, Jun SY, Paduch D, etal. Stages at presentation, prognostic factors, and outcome of breast cancer in males. Am J Surg 1999;177(5):379-383 (Pubitemid 29252805)
183. Herman K, Lobaziewicz W, Skotnicki P, etal. Male breast cancer. Does the prognosis differ compared to female? Neoplasma 2000;47(3):191-195
184. van Geel AN, van Slooten EA, Mavrunac M, Hart AA. A retrospective study of male breast cancer in Holland. Br J Surg 1985;72(9):724-727 (Pubitemid 16215174)
185. Park S, Kim JH, Koo J, et al. Clinicopathological characteristics of male breast cancer. Yonsei Med J 2008;49(6):978-986
186. Botan RD, Alvares MN, Hassan A. Male breast cancer: Prognostic factors evaluation in a 35-year service. J Clin Oncol 2009;27(suppl):abstract e11618
187. Andre S, Fonseca I, Pinto AE, et al. Male breast cancer-a reappraisal of clinical and biologic indicators of prognosis. Acta Oncol 2001;40(4):472-478 (Pubitemid 32682031)
188. Rudan I, Rudan N, Basic N, et al. Differences between male and female breast cancer. II. Clinicopathologic features. Acta Med Croatica 1997;51(3):129-133
189. Clark JL, Nguyen PL, Jaszcz WB, et al. Prognostic variables in male breast cancer. Am Surg 2000;66(5):502-511 (Pubitemid 30252485)
190. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist 2005;10(7):471-479 (Pubitemid 41266328)
191. SEER. Surveillance, epidemiology, and end results program. 1988 - 2001. Available from: http://seer.cancer.gov/publications/survival/
192. Lanitis S, Rice AJ, Vaughan A, et al. Diagnosis and management of male breast cancer. World J Surg 2008;32(11):2471-2476
193. Schaub NP, Maloney N, Schneider H, et al. Changes in male breast cancer over a 30-year period. Am Surg 2008;74(8):707-11; discussion 11-12
194. SEER Cancer statistics review, 1975 - 2005; Breast. Available from: http://seer.cancer.gov/csr/1975-2006/index.html
195. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008;26(22):3785-3790